its hepatotoxicity. It is, however, used in the synthesis of refrigerants and production of semiconductors, as a fumigant, and in the processing of fats, oils, and rubber (3) . Industrial emission is the major source of CCl 4 in the air. It is found in low levels in ambient air and water (3) .
CCl 4 is rapidly metabolized by mixed function cytochrome P450 oxygenases of the endoplasmic reticulum (ER) 2 resulting in the generation of CCl 3 ⅐ (4, 5). Adduct formation between CCl 3 ⅐ and DNA is believed to initiate hepatic cancer (5) . CCl 3 ⅐ can also react with oxygen to form CCl 3 OO ⅐ (4, 5). CCl 3 OO ⅐ initiates a chain reaction leading to lipid peroxidation, changes in membrane permeability, and loss of calcium homeostasis. In addition, tissue lipid levels increase (see below). The initial cellular injury subsequently takes the form of inflammation (5, 6) , and the chronic effects of CCl 4 exposure include fatty degeneration, fibrosis, hepatocellular death, and carcinogenicity (5) .
After oral administration, CCl 4 concentrates in the liver. Early biochemical changes are obvious in the first couple of hours, and tissue necrosis is visible after 5 h. Around 12 h, central zone necrosis is evident (5) . CCl 4 decreases secretion of triglycerides as part of very low density lipoproteins and increases hepatic triglyceride by 195% within 3 h in rats (7) . Thus, a distinctive feature of CCl 4 toxicity is the rapidity of triglyceride accumulation in the liver due to a failure in their secretory mechanisms (2, 4, 5) . This failure has been largely attributed to unspecified functional impairment in the Golgi apparatus (5) , and the need to study the possible effects of chlorinated methanes on the molecular events involved in triglyceride secretion has been emphasized (4) .
Triglyceride secretion requires assembly and secretion of lipoproteins by the liver and intestine, which is critically dependent on apolipoprotein B (apoB) and microsomal triglyceride transfer protein (MTP) (8 -10) . ApoB serves as a structural protein, and MTP present in the ER is a required chaperone for the assembly of triglyceride-rich lipoproteins. MTP transfers several lipids, and its phospholipid transfer activity is sufficient for lipoprotein production (11) . In addition, MTP physically associates (12) with the N terminus of apoB (13) . Thus, MTP is believed to bind and transfer lipids to nascent apoB forming primordial lipoprotein particles (8, 9) . Expression and ablation of MTP affects triglyceride secretion indicating that it is rate-limiting (14, 15) . Recently, MTP has been * This work was supported by National Institutes of Health Grant HL-64272 (to M. M. H.) and a postdoctoral fellowship from the American Heart Association, Heritage Affiliate (to X. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom correspondence should be addressed: SUNY Downstate Medical Center, 450 Clarkson Ave., Brooklyn, NY 11203. E-mail: mhussain@ downstate.edu.
shown to be involved in the lipidation (16) of CD1d, glycolipid antigen-presenting molecule, and in the maturation of NKT cell development (17) . Moreover, MTP levels have been inversely correlated with hepatosteatosis in individuals infected with type III hepatitis C virus (18) . Decreased MTP levels have also been suggested to initiate alcoholic steatosis in rats (19) . MTP inhibitors are known to cause steatosis (20, 21) , but the role MTP plays in the development of other forms of steatosis is unknown. Here we show that CCl 4 induces post-translational degradation of MTP and causes steatosis.
EXPERIMENTAL PROCEDURES

Materials
Rabbit anti-mouse apoB48/apoB100 (Biodesign, K23300R), goat anti-human apoAI and apoB (Biodesign), rabbit anti-protein disulfide isomerase (anti-PDI, Stressgen, SPA-890), rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Chemicon, MAB374), anti-MTP (BD Transduction Laboratories, 612022), rabbit anti-ubiquitin (Abcam, Inc. ab7780), [ 35 
Animals
C57Bl/6J mice (The Jackson Laboratory) were housed in an air-conditioned room at 22°C with a 12-h lighting schedule and fed rodent chow. Male 10 -12-week-old mice were used in this study. Food was removed the night before the experiments. Experimental mice received CCl 4 in olive oil. Control mice received an equal volume of oil and saline. Blood was collected from the heart, and serum lipid levels were determined in plasma using commercial kits (Thermo Trace). Cholesterol and triglyceride in high density lipoproteins (HDL) were measured after the precipitation of apoB-lipoproteins with phosphotungstate magnesium chloride (22) .
Cells
McA-RH777 cells (23) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine and 10% horse serum (Invitrogen). Primary enterocytes were isolated and cultured as described (24) . HepG2 and Caco-2 cell were cultured as described previously (25, 26) . Human apoB and apoAI secreted from cells were measured by enzyme-linked immunosorbent assay (23, 27) .
Methods
MTP Activity
Assays-To measure MTP activity, 100 g of liver and intestine were homogenized in 1 ml of buffer K (1.0 mM EGTA, 1 mM Tris-HCl, and mM MgCl 2 ) and centrifuged at 50,000 rpm for 1 h. The supernatant was used to measure MTP activity (28, 29) . For in vitro activity assays, MTP purified from bovine liver or mice intestinal and liver microsomal proteins were incubated with different concentrations of olive oil or CCl 4 in oil for 30 min in the presence of donor and acceptor vesicles. Changes in fluorescence due to lipid transfer by MTP were recorded and used to determine the effect of CCl 4 on MTP activity.
Lipid Synthesis-To measure lipid synthesis and secretion, cells were labeled with 5 Ci/ml [ 3 H]glycerol with or without CCl 4 for 4 h. The media were collected, and the cells were washed twice with cold phosphate-buffered saline. Total lipids in the cells and medium were then extracted with chloroformmethanol (2:1, v/v). The organic solvent was evaporated, and the residues were dissolved in isopropanol and spotted on a thin layer chromatographic plate. Radiolabeled triglycerides and phospholipids were separated using hexanes/ethyl ether/acetic acid (80:20:2) as a developing solvent. Lipids were visualized by exposure to iodine vapors; bands corresponding to the marker lipids were scraped, and radioactivity was measured by liquid scintillation counting (26) .
Metabolic Labeling and Immunoprecipitation-Cells were preincubated in methionine-free Dulbecco's modified Eagle's medium for 30 min and pulse-labeled with [ 35 S]methionine (100 -200 Ci/ml). For pulse-chase experiments, cells were incubated with [ 35 S]methionine (200 Ci/ml) for 2 h in methionine-deficient media supplemented with 0.1% bovine serum albumin. Cells were washed and chased in Dulbecco's modified Eagle's medium containing 100 M methionine in the presence and absence of CCl 4 in Me 2 SO for different times. For immunoprecipitation, cell lysates were prepared in 50 mM Tris-HCl, pH 8.0, containing 150 mM NaCl, 0.015% phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 1 mM EDTA, 1% sodium deoxycholate, 1% Triton, 1% SDS. Cell lysates were incubated at 70°C for 15 min to ensure complete cell lysis and diluted with lysis buffer to achieve a SDS concentration of 0.1% (w/v) as reported (23, 30) . Media were collected and centrifuged at 13,000 rpm for 10 min to remove cell debris. Supernatants (0.9 ml) were combined with 0.1 ml of 10ϫ lysis buffer containing 1% SDS. Cell lysates and media were incubated with antibodies (1:100 dilution) for 2 h and then with 20 l of protein A/G-Sepharose (10% solution) for an additional 2 h. Immunocomplexes were collected by centrifugation, washed three times with 10 mM Tris, pH 7.5, containing 0.1 M NaCl and 1% Triton, eluted in 50 l of sample buffer, separated on SDS-polyacrylamide gel, and exposed to a phosphorimaging screen. Radioactivity in apolipoproteins was measured by liquid scintillation counting.
Western Blot Analysis-Proteins were separated under nonreducing conditions, transferred to nitrocellulose membranes, blocked for 2 h in 20 mM Tris, 137 mM NaCl, pH 7.5, containing 0.1% Tween 20 and 5% nonfat dry milk at room temperature. The blots were washed three times and incubated overnight at 4°C in the same buffer containing 0.5% dry milk and a primary antibody (1:1000 dilution), washed, and then incubated with mouse horseradish peroxidase-conjugated secondary antibody (1:4000) in 1.0% skim milk for 1 h at room temperature. Immune reactivity was detected by chemiluminescence.
For subcellular fractionation experiments, cells were homogenized using a syringe with a 25-gauge needle (10 strokes) and centrifuged (500 ϫ g, 10 min, 4°C; Beckman GS-15R centrifuge). The postnuclear supernatant was then centrifuged (3,000 ϫ g, 10 min, 4°C) to get the heavy mitochondrial pellet. To isolate the microsomal fraction, the postmitochondrial supernatant was centrifuged at 100,000 ϫ g for 1 h at 4°C using a Beckman tabletop Ultracentrifuge TLA-110 rotor. The remaining supernatant was designated as the cytosolic fraction as reported previously (31, 32) . The microsomal pellet and the supernatant proteins were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with polyclonal anti-calnexin antibody (Stressgen; 1:2,000 dilution) or anti-MTP antibody (1:2,000 dilution).
To detect ubiquitin-conjugated proteins, cell or tissue homogenates were prepared in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS and incubated with protein A and anti-MTP antibodies for 2 h. Immunocomplexes were washed, resolved on SDS-polyacrylamide gels, and blotted onto polyvinylidene difluoride membranes. For detection of ubiquitinylated proteins, membranes were incubated with antibodies against ubiquitin or MTP. After 2 h, membranes were washed and incubated with the corresponding secondary antibody tagged with horseradish peroxidase, signals were detected by enhanced chemiluminescence (Amersham Biosciences).
Analyses of Gene ExpressionsTotal tissue RNA was isolated from frozen tissues or cells using TRIzol (Invitrogen) (33, 34) . RNA was treated with DNase I at 37°C followed by inactivation at 75°C for 5 min. cDNA was synthesized from total RNA using SuperScript Firststrand Synthesis System (Invitrogen) and random hexamer primers. Real-time PCR measurements of individual cDNAs were performed in triplicate by TaqMan probe or SYBR Green methods using an ABI Prism 7000 (Applied Biosystems). The primer-probe sets used for MTP and 18 S rRNA were as fol- lows: mouse MTP forward primer, 5Ј-ACG GCC ATT CCC ATT GTG-3Ј; reverse primer, 5Ј-GCC AGA GCT CCG AGA GAG AA-3Ј; fluorescence probe, 5Ј-(Fam)-GTC TTC CAG AGC CAC TGT AAA GGA TGTC-3Ј-(Tamra). 18 S rRNA forward primer, 5Ј-AGTCC CTTGCC CTTTG TACACA-3Ј; reverse primer, 5Ј-GATCC GAGGG CCTCA CTAAAC-3Ј; fluorescence probe, 5Ј-(Fam)-CGCCCGTCGCTACTACC-GATTGGT-3Ј-(Tamra). Rat MTP forward primer, 5Ј-GTC-ACGATAACGGCTGTCAATG-3Ј; reverse primer, 5Ј-TGC-CCTTGAAGAAGATGCTCTTCTC-3Ј; fluorescence probe, 5Ј (Fam) CGAAAATGCGGGTCAGCAGAGAGG-6TAM-RA3Ј (Tamra). GAPDH mRNA was used as an internal control (Applied Biosystems) (35) .
Statistical Analysis-All determinations were made in triplicate or quadruplicate and reported as the mean Ϯ S.D. Treatment groups were subjected to one-way analysis of variance and Bonferroni's test for multiple comparisons. Values of p Ͻ 0.05 were considered significant. Time course studies revealed maximum reductions in plasma triglycerides at 4 h (Fig. 1E, total) . Subsequently, there was a trend toward an increase in their plasma levels. In fact, plasma lipids reverted to normal levels after 24 h (data not shown). CCl 4 mainly decreased apoB-lipoprotein triglyceride (Fig. 1E , apoB-lipoproteins) without affecting HDL (Fig. 1E, HDL) . Total plasma cholesterol levels also significantly decreased with time in CCl 4 -fed mice (Fig. 1F, total) . Again, apoB-lipoprotein (Fig. 1F , apoB-lipoprotein) cholesterol levels were significantly reduced and HDL levels were unaffected (Fig. 1F, HDL) . Tissue lipid analyses revealed that intestinal and hepatic triglyceride increased (ϳ3-fold) up to 4 h and then decreased at 6 h (Fig. 1G) . Similarly, hepatic and intestinal cholesterol levels increased until 4 h and started to decline later (Fig. 1H ). These studies show that a single dose of CCl 4 significantly decreases plasma apoB-lipoproteins and 4 . After 4 h, MTP activity was measured in the intestine (A) and liver (B). In addition, MTP and GAPDH protein levels were measured in the intestine (C) and liver (D). To study time course of MTP loss, mice were gavaged with 1 mg/kg CCl 4 . MTP activity was measured at different indicated times in the intestine (E) and liver (F). Furthermore, MTP and GAPDH protein levels were determined by Western blot analysis in the intestine (G) and liver (H). MTP activity, MTP and GAPDH protein levels in the intestine and liver were determined using 100 g of microsomal proteins. Each point represents the mean Ϯ S.D. *, p Ͻ 0.05; **, p Ͻ 0.01; significantly different from oil control group.
RESULTS
CCl 4 Decreases Plasma ApoBlipoproteins and Increases Hepatic and Intestinal Lipid Levels-To
increases intestinal and hepatic triglyceride and cholesterol levels in a time-dependent fashion. Increases in liver triglyceride levels have been observed in CCl 4 -exposed animals (2, 4, 5); however, intestinal steatosis has not yet been appreciated.
CCl 4 Decreases MTP in Mice-Because CCl 4 had a major effect on plasma apoB-lipoproteins, we studied its effect on MTP. Mice were fed with increasing amounts of CCl 4 , and triglyceride transfer activity of MTP was measured after 4 h. (28, 29) . Liver (B) and intestinal (C) proteins (100 g) were also incubated with increasing concentrations of CCl 4 to study the effect of CCl 4 on triglyceride transfer activity. Increasing CCl 4 concentrations decreased MTP activity in the intestine ( Fig. 2A) and liver (Fig. 2B) . Western analyses showed significant decrease in MTP but no change in cytosolic marker GAPDH (Fig. 2, C and D) . Time course studies showed that MTP activity decreased in the liver and the intestine with maximum reduction (ϳ75%) evident at 4 h (Fig. 2, E and F) . In addition, there was a time-dependent loss of protein in these tissues (Fig. 2, G and H) . These studies indicate that CCl 4 decreases MTP protein and activity in different tissues.
To address whether CCl 4 has a direct effect on MTP, we studied its effect on the purified and cellular MTP. CCl 4 had no inhibitory effect on the lipid transfer activity of purified MTP (Fig. 3A) . Furthermore, it did not alter hepatic and intestinal MTP activities (Fig.  3, B and C) (Fig. 4A) . Amounts of apoB were significantly lower in cells treated with higher concentrations of CCl 4 . However, this treatment had no effect on cellular apoAI levels (Fig. 4B) . Next, we measured the amounts of radiolabeled MTP and GAPDH in cells treated with increasing CCl 4 concentrations. This treatment significantly decreased cellular MTP without affecting GAPDH levels (Fig. 4C) . We also measured MTP activity in enterocytes exposed to different CCl 4 levels (Fig. 4D ) and observed that MTP activity was reduced in cells exposed to higher levels of CCl 4 . These studies showed that CCl 4 treatment decreases MTP but does not affect GAPDH levels. Moreover, it decreased apoB secretion without affecting apoAI secretion.
Studies were then performed in human colon carcinoma Caco-2 and hepatoma HepG2 cells (Fig. 5) . CCl 4 decreased secretion of lipids (Fig. 5A) and apoB ( Fig. 5B ) but had no effect on apoAI secretion in Caco-2 cells. Furthermore, it decreased cellular MTP activity (Fig. 5C) . Analyses of mRNA levels revealed that CCl 4 had no effect on apoB, apoAI, or MTP mRNA levels (Fig. 5D) . Exposure of HepG2 to increasing amounts of CCl 4 also resulted in decreased secretion of lipids (Fig. 5E ) and apoB (Fig. 5F ) consistent with other toxicity studies in these cells (36) . In contrast, this treatment had no effect on apoAI secretion. Again, CCl 4 decreased MTP activity (Fig.  5G ) but had no effect on mRNA levels of apoB, apoAI, or MTP (Fig. 5H) . These studies indicate that CCl 4 specifically decreases apoB secretion by reducing MTP activity. Decrease in MTP was not due to changes in its mRNA levels, excluding transcriptional repression mechanisms.
Incubation of rat hepatoma McA-RH7777 cells with increasing concentrations of CCl 4 significantly decreased triglyceride and phospholipid secretion (Fig. 6, A and B) , increased cellular triglycerides, but not phospholipids and proteins (Fig. 6B) , and reduced apoB secretion without affecting apoAI secretion (Fig.  6C ) consistent with the inhibition of lipid secretion by CCl 4 in primary rat hepatocytes (7, 37, 38) . In these cells, MTP protein decreased, but protein disulfide isomerase (ER enzyme) and GAPDH remained unaltered (Fig. 6D) . In contrast to its effects on protein levels, CCl 4 had no effect on MTP mRNA levels eliminating the model in which changes in mRNA lead to differences in protein activities (Fig. 6E) . In short, CCl 4 reduces MTP activity in both intestinal and liver cells, decreases lipoprotein secretion, and increases intracellular triglyceride as it does in mice. 3 H]glycerol (5 Ci/ml). Lipids were extracted from media and separated on thin layer plates, and bands corresponding to triglycerides (TG) and phospholipids (PL) were counted. The media were also used to measure apoB and apoAI by enzyme-linked immunosorbent assay (B). Cells were used to measure triglyceride transfer activity (C) and mRNA levels (D) by quantitative reverse transcriptase-PCR. E-H, human hepatoma HepG2 cells were incubated with different amounts of CCl 4 for 4 h. For lipid analyses, these cells also received [ 3 H]glycerol (E). Media were used for lipid extraction, as described in A and under "Experimental Procedures," and to measure apoB and apoAI by enzyme-linked immunosorbent assay (F). Cells were used to measure MTP activity (G) as well as mRNA quantifications (H). *, p Ͻ 0.05; **, p Ͻ 0.01, compared with controls.
CCl 4 Induces Post-translational Degradation of MTP Involving Ubiquitin and Proteasomes-The
tein with no change in mRNA levels could be because of reduced synthesis or enhanced post-translational degradation. To study the effect of CCl 4 on MTP synthesis, McA-RH7777 cells were treated with CCl 4 for 4 h and then radiolabeled for 5-15 min. MTP synthesis was similar in control and CCl 4 -treated cells (Fig.  7A) . Moreover, the syntheses of apoB, apoAI, and GAPDH were not affected indicating that CCl 4 (Fig. 7B) . Similarly, the disappearance of apoB was greater in CCl 4 -exposed cells compared with controls. In contrast, apoAI and GAPDH levels were not altered. Protein analyses in the media revealed that CCl 4 inhibited apoB, but not apoAI, secretion. These studies indicate that CCl 4 induces post-translational degradation of MTP. The decrease in apoB is consistent with the knowledge that inhibition of MTP reduces apoB secretion (39) .
Attempts were made to understand mechanisms involved in the post-translational degradation of MTP. The elimination of misfolded proteins and regulated enzymes involves retrograde translocation across the ER membrane and proteolysis by ubiquitin-proteasomes (40, 41) . To determine whether proteasomes are involved in MTP degradation, McA-RH7777 cells were treated with inhibitors (lactacystin, MG132, ALLN) along with CCl 4 . Proteasomal inhibitors abolished CCl 4 -induced MTP degradation (Fig. 7C) . Next, we studied the effect of proteasomal inhibitors on the post-translational degradation of MTP. Cells were radiolabeled with [ 35 S]methionine and then chased in the media containing CCl 4 with or without different inhibitors (Fig.  7D) . Again, all of the inhibitors prevented post-translational degradation of MTP to different extents. We then asked whether the protected MTP retains its ability to transfer triglycerides. Cells were incubated with CCl 4 in the presence and absence of lactacystin, and the amounts of MTP protein as well as its activity were measured (Fig.  7E) . Incubation of cells with lactacystin restored MTP protein and activity (Fig. 7E) . We then determined whether preincubation of cells with lactacystin would protect MTP from degradation. Preincubation of cells with lactacystin provided no protection against the loss of MTP protein and activity (Fig. 7F) underscoring the importance for its continuous presence to inhibit degradation. These data indicate that CCl 4 induces MTP degradation involving proteasomes. . Lipids were extracted from media (A and B) and cells (B) and separated on thin layer plates; triglycerides (TG) and phospholipids (PL) were quantified (A) (22, 26) . In B, counts present in control cells (0 mM) were normalized to 100%. C, cells were treated with different amounts of CCl 4 for 4 h and metabolically labeled with [ 35 S]methionine. Media were immunoprecipitated sequentially with anti-apoB and anti-apoAI antibodies and exposed to phosphorimaging screens, and bands were visualized. Data from a representative experiment are shown. Bands from three different experiments were quantified; data are presented as mean Ϯ S.D. D, MTP, protein disulfide isomerase (PDI), and GAPDH were immunoprecipitated sequentially from cells, exposed, and quantified. E, cells were used for either MTP activity measurements or total RNA isolation. The MTP activity and MTP/18 S rRNA ratio in control cells were normalized to 100%. *, p Ͻ 0.05; ** p Ͻ 0.01, significantly different from control group.
A key step in proteasomal degradation is the ubiquitinylation of proteins (40) . CCl 4 treatment enhanced ubiquitinylation of MTP (Fig. 7G) , and the recovery of ubiquitinylated MTP increased in the presence of lactacystin (Fig. 7H) indicating that MTP degradation involves ubiquitinylation. To identify the site of degradation, MTP activity was measured in microsomes and cytosol. MTP was mainly present in microsomes (Fig. 7I) . CCl 4 decreased MTP in microsomes with no increase in the cytosol indicating no significant translocation to cytosol for disposal. Thus, CCl 4 -induced loss of MTP protein from microsomes involves ubiquitinylation and ER-associated proteasomal degradation.
Covalent Modification of MTP by CCl 4 -To understand how MTP is targeted for degradation, we hypothesized that CCl 4 might covalently modify MTP. Incubation of cells with 14 CCl 4 resulted in its incorporation into MTP, and the amounts of modified MTP increased when cells were treated with lactacystin (Fig. 7J) . Immunoprecipitation followed by exposure to phosphorimaging screens for 1 month did not reveal any incorporation of label in apoB, apoAI (data not shown), or GAPDH (Fig. 7J) . Ketoconazole, an inhibitor of mixed function oxygenases (42), inhibited MTP modification (Fig. 7J ) consistent with the understanding that bioactivation of CCl 4 by these enzymes is required to inhibit lipid secretion by hepatocytes (7, 37, 38) . We interpret these studies to suggest that CCl 3 ⅐ generated by cytochrome P450 oxygenases covalently attaches to MTP and that this modification targets MTP for proteasomal degradation.
MTP Inhibitor Does Not Induce Its Degradation-To determine whether MTP degradation is involved in other forms of steatosis, we compared the effect of CCl 4 with an MTP antagonist, BMS197636 (43) . Both CCl 4 and BMS197636 decreased lipid secretion (Fig. 8A ) and increased cellular triglyceride but not phospholipid levels (Fig. 8B ). Cells treated with the inhibitor and CCl 4 had significantly reduced MTP activity (Fig. 8C) . CCl 4 significantly reduced MTP protein, but the inhibitor did not (Fig. 8D) . Thus, CCl 4 and MTP antagonist cause steatosis by different mechanisms. MTP antagonists inhibit lipid transfer activity, whereas CCl 4 induces protein degradation. 
Lactacystin Partially Prevents CCl 4 -induced Steatosis in Mice-
To determine whether inhibition of proteolysis could prevent CCl 4 toxicity, mice were first fed with saline or lactacystin. After 30 min, lactacystin-fed animals were gavaged with CCl 4 with or without lactacystin (Fig. 9) . MTP protein was decreased in the intestine and liver of CCl 4 -fed mice, and lactacystin partially protected the loss of MTP protein and activity in these tissues (Fig. 9, A and B) . The ubiquitinylated MTP levels increased in the tissues of lactacystin-fed mice (Fig. 9, C-D) . Furthermore, lactacystin partially restored MTP activity in these tissues (Fig. 9, E and F) . Accumulation of triglyceride and cholesterol in the intestine (Fig. 9G) and liver (Fig. 9H) was prevented when mice were fed with CCl 4 and lactacystin. Moreover, the decreases in plasma triglyceride (Fig. 9I) and cholesterol (Fig.  9J ) associated with CCl 4 toxicity were avoided by this treatment, mainly because of partial restoration of apoB100 and apoB48 lipoproteins (Fig. 9K) . These studies indicate that proteasomal inhibitors may be useful in treating acute CCl 4 toxicity.
DISCUSSION
It is known that the exposure to CCl 4 induces cellular accumulation of triglycerides by unknown mechanisms. Here, we show that MTP degradation after short-term exposure to CCl 4 is the major mechanism leading to the cellular accumulation of lipids. Furthermore, these studies demonstrate for the first time that CCl 4 exposure results in covalent modification of MTP followed by its rapid and specific degradation involving ubiquitinylation and proteasomes (Fig 10) . We also show that the prevention of MTP degradation by proteasomal inhibitors affords protection against CCl 4 toxicity. Thus, covalent modification of MTP leading to its destruction is a key early and essential step in the onset of CCl 4 -induced steatosis.
Nothing is known about the mechanisms involved in the disposal of MTP under normal and pathologic conditions. MTP is believed to have a long half-life (44) , and its levels are regulated mainly at the transcriptional level (45, 46) . We recently showed that intestinal and hepatic MTP levels exhibit diurnal variations due to changes in transcription during 24 h. 3 Here we show that the major mechanism involved in the loss of MTP by CCl 4 is the induction of its degradation by ubiquitin-proteasome pathway. In contrast, MTP antagonist does not induce MTP degradation. Thus, only under certain conditions is MTP removed by proteasomes. It is likely that this mechanism may play a role in the onset of some forms of steatosis.
At this time we do not know the subcellular site of MTP degradation. Our data clearly show that MTP degradation is a post-translational process. Thus, it is not linked to the site of MTP mRNA translation. It is possible that MTP is modified and degraded at a specialized subcompartment that is involved in apoB-lipoprotein assembly or in a compartment that is enriched in P450 oxygenases.
Loss of MTP activity has been shown to result in the accumulation of lipids in the liver of hepatitis C virus-infected individuals (18) . Furthermore, a significant correlation was observed between the decreases in MTP mRNA levels and the degree of steatosis in liver biopsies. In addition, several MTP antagonists have been shown to cause steatosis (20, 21) . In contrast, short-term exposure to CCl 4 by inhibiting proteasomal degradation of MTP. Inhibition of proteasomal degradation increases accumulation of the modified MTP (Figs. 7-9 ). This indicates that CCl 4 modification does not inhibit its lipid transfer activity and that nondegraded, modified protein is able to transfer triglyceride and assist in its secretion avoiding steatosis. Thus, the mode of action of CCl 4 is different from that of MTP antagonist. CCl 4 induces protein degradation without affecting its lipid transfer activity, whereas MTP antagonists inhibit lipid transfer activity without causing its destruction.
Incubation of cells with 14 CCl 4 resulted in the covalent labeling of MTP (Fig. 7J) . To explain this, we proposed that CCl 4 is converted to CCl 3 ⅐ and these free radicals react with MTP ( Fig  10) . It has been demonstrated that CCl 4 undergoes cleavage resulting in the generation of CCl 3 ⅐ and covalent modification of proteins and lipids (2, 4 -6, 48 ). Significant evidence indicates that cytochrome P450 oxygenases play a key role in this process. For example, induction of these enzymes leads to increased hepatotoxicity, and their inhibition protects against CCl 4 toxicity. Organisms with low activity, such as newborns of many species and chicken, are less sensitive to CCl 4 . Moreover, CYP2E1 knock-out mice are relatively more resistant to CCl 4 hepatotoxicity compared with controls (49) . We observed that inhibition of these oxygenases avoids MTP modification. Thus, it is likely that the generation of CCl 3 ⅐ by cytochrome P450 is a key step in MTP modification. Thus far, no specific protein Intestinal (E) and hepatic (F) microsomal contents were used to measure MTP activity. Intestinal (G) and liver (H) tissues were also used to measure lipid levels. Plasma was used to measure total and apoBlipoprotein triglyceride (I) and cholesterol (J). ApoB100, apoB48, and apoAI in plasma were visualized by Western analysis (K). *, p Ͻ 0.05; **, p Ͻ 0.01, compared with saline group. ⅐ and Cl ⅐ ) by cytochrome P450 oxygenases. MTP is covalently modified by CCl 3 ⅐ , ubiquitinylated, and degraded by proteasomes. This leads to increased accumulation of triglycerides and cholesterol in the tissues. If proteasomal degradation of MTP is inhibited by lactacystin, the CCl 4 toxicity is averted in part because the protected MTP is able to assist in lipoprotein assembly and in the secretion of triglycerides. modified by CCl 3 ⅐ has been identified, and it is assumed that it is probably a nonspecific process. Our identification that CCl 4 covalently modifies MTP may lead the way to the identification of other proteins that are modified by CCl 3 ⅐ .
CYP2E1 has been recognized as the major enzyme involved in the bioactivation of CCl 4 by the liver. However, the intestine is known to express several P450 oxygenases (50) . The current understanding is that CYP2B1 or CYP2B2, and possibly CYP3A, can also metabolize CCl 4 and form the trichloromethyl radical, CCl 3 ⅐ (5). More experiments are required to identify the enzyme involved in CCl 4 bioactivation in the intestinal cells.
We do not know why MTP is so susceptible to CCl 4 attack. It is possible that CCl 4 acts like a lipid, a hydrophobic molecule. This is supported by the observations that the major molecules damaged by CCl 4 are the membrane lipids. Another possible explanation is that the generation of CCl 3 ⅐ occurs near the membrane and thus membrane lipids are more prone to modification. Because MTP is a lipid transfer protein, it might attempt to transfer CCl 3 ⅐ from the membrane and during this process become modified and targeted for degradation. The preferential and rapid degradation of MTP after CCl 4 exposure suggests that MTP may transfer as yet unidentified reactive species and needs further evaluation. If MTP is involved in the transfer of such reactive molecules, their identification might shed new light on the role of MTP in the assembly and secretion of apoB-lipoproteins and in the maintenance of membrane integrity.
Surveillance of the structural and functional integrity of proteins is of utmost importance to cells. Thus, we think that the modification of MTP after CCl 4 exposure is sensed as deleterious and that cells target it for degradation. To our knowledge this is a novel mechanism explaining the toxicity involving environmental toxins. It remains to be determined whether proteasomal degradation of MTP might occur under other conditions such as exposure to other environmental toxins, oxidizing agents, or free radicals. It is possible that the degradation of proteins damaged by environmental toxins may be a reason for cytotoxicity. It is also likely that MTP degradation might be involved in the development of certain forms of steatosis such as those observed in hepatitis C virus infection (18) and alcoholic and nonalcoholic fatty liver, and it remains to be determined whether inhibiting protein degradation might provide protection against these forms.
Knowledge about the molecular processes involved in CCl 4 -induced hepatotoxicity has led to the use of antioxidants and mitogens to alleviate symptoms. Mitogens restore cellular methylation, and antioxidants preserve calcium homeostasis. In addition, antagonists of CYP450 have been shown to alleviate toxicity. On the other hand, compounds that induce cytochrome or delay tissue repair enhance CCl 4 toxicity (4, 5) . Here, we show that proteasomal inhibitors can also provide protection against CCl 4 -induced cytotoxicity. Proteasomal inhibitors are in clinical trial for the treatment of cancer (51) . Perhaps they could also be evaluated for their efficacy in treating some forms of steatosis.
In summary, we have described the novel pathway that CCl 4 employs to induce steatosis, showing that CCl 4 exposure leads to covalent modification of MTP and its degradation by proteasomes. Inhibition of MTP degradation leads to prevention of cellular lipid accumulation. It remains to be determined whether the protection of MTP degradation would also avoid cellular necrosis and other pathologic indications associated with CCl 4 toxicity. Moreover, these studies suggest that the loss MTP may be involved in the development of other forms of steatosis.
